Rectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Rectal Cancer Drugs Development Market Overivew
Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.
The Rectal cancer – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Rectal cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal cancer and features dormant and discontinued projects.
Key Targets in the Rectal Cancer Pipeline Drugs Market
In the Rectal Cancer pipeline drugs market the key targets are Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, DNA, Prostaglandin E2 Receptor EP4 Subtype, DNA Topoisomerase I, Human Papillomavirus Protein E7, Vascular Endothelial Growth Factor Receptor 2, Adenosine Receptor A2a, Adenosine Receptor A2b, Cannabinoid Receptor 1.
Rectal Cancer Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Rectal Cancer Pipeline Drugs Market
Programmed Cell Death 1 Ligand 1 Inhibitor has the highest number of pipeline products followed by Programmed Cell Death Protein 1 Antagonist, DNA Synthesis Inhibitor, Prostaglandin E2 Receptor EP4 Subtype Antagonist, DNA Topoisomerase I Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Adenosine Receptor A2a Antagonist, Adenosine Receptor A2b Antagonist, Cannabinoid Receptor 1 Agonist, and Cannabinoid Receptor 2 Agonist.
Rectal Cancer Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Rectal Cancer Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Rectal Cancer pipeline drugs market are Intravenous, Oral, Subcutaneous, Intravenous Drip, Buccal, Intramuscular, Intraperitoneal, Intratumor, Parenteral, Sublingual, Submucosal, Topical, and Vaginal. Intravenous has the maximum number of pipeline products.
Rectal Cancer Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Rectal Cancer Pipeline Drugs Market
The key molecule types in the Rectal Cancer pipeline drugs market are Small Molecule, Monoclonal Antibody, Fusion Protein, Cell Therapy, Recombinant Vector Vaccine, Aptamer, Biologic, Monoclonal Antibody Conjugated, and Oncolytic Virus.
Rectal Cancer Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Rectal Cancer Pipeline Drugs Market
The major companies in the Rectal Cancer pipeline drugs market are Eisai Co Ltd, GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co Ltd, Merck KGaA, Novartis AG, SQZ Biotechnologies Co, Advaxis Inc, Alkermes Plc, Amphivena Therapeutics Inc, and Apexigen Inc.
Rectal Cancer Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Rectal Cancer Pipeline Drugs Market Overview
Key Targets | Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, DNA, Prostaglandin E2 Receptor EP4 Subtype, DNA Topoisomerase I, Human Papillomavirus Protein E7, Vascular Endothelial Growth Factor Receptor 2, Adenosine Receptor A2a, Adenosine Receptor A2b, Cannabinoid Receptor 1 |
Key Mechanisms of action | Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, DNA Synthesis Inhibitor, Prostaglandin E2 Receptor EP4 Subtype Antagonist, DNA Topoisomerase I Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Adenosine Receptor A2a Antagonist, Adenosine Receptor A2b Antagonist, Cannabinoid Receptor 1 Agonist, and Cannabinoid Receptor 2 Agonist |
Key Routes of Administration | Intravenous, Oral, Subcutaneous, Intravenous Drip, Buccal, Intramuscular, Intraperitoneal, Intratumor, Parenteral, Sublingual, Submucosal, Topical, and Vaginal |
Key molecule types | Small Molecule, Monoclonal Antibody, Fusion Protein, Cell Therapy, Recombinant Vector Vaccine, Aptamer, Biologic, Monoclonal Antibody Conjugated, and Oncolytic Virus |
Major companies | Eisai Co Ltd, GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co Ltd, Merck KGaA, Novartis AG, SQZ Biotechnologies Co, Advaxis Inc, Alkermes Plc, Amphivena Therapeutics Inc, and Apexigen Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The pipeline guide reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rectal Cancer therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rectal Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Rectal Cancer
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rectal Cancer
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Alkermes Plc
Amphivena Therapeutics Inc
Apexigen Inc
AptaBio Therapeutics Inc
Arcus Biosciences Inc
AstraZeneca Plc
BeiGene Ltd
Beijing Konruns Pharmaceutical Co Ltd
BioAtla Inc
Biomimetix JV LLC
Bristol-Myers Squibb Co
CytomX Therapeutics Inc
Diverse Biotech Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genexine Inc
Genome & Co
GlaxoSmithKline Plc
Harbin Gloria Pharmaceuticals Co Ltd
Hutchison MediPharma Ltd
Incyte Corp
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
LipoMedix Pharmaceutical Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Novartis AG
Oncolys BioPharma Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Pieris Pharmaceuticals Inc
Precigen Inc
Privo Technologies Inc
Sanofi
Shanghai Haihe Biopharma Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
SQZ Biotechnologies Co
Taiho Oncology Inc
Teon Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Rectal Cancer pipeline drugs market?
In the Rectal Cancer pipeline drugs market the key targets are Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, DNA, Prostaglandin E2 Receptor EP4 Subtype, DNA Topoisomerase I, Human Papillomavirus Protein E7, Vascular Endothelial Growth Factor Receptor 2, Adenosine Receptor A2a, Adenosine Receptor A2b, Cannabinoid Receptor 1.
-
What are the key mechanisms of action in the Rectal Cancer pipeline drugs market?
In the Rectal Cancer pipeline drugs market the key mechanisms of action are Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, DNA Synthesis Inhibitor, Prostaglandin E2 Receptor EP4 Subtype Antagonist, DNA Topoisomerase I Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Adenosine Receptor A2a Antagonist, Adenosine Receptor A2b Antagonist, Cannabinoid Receptor 1 Agonist, and Cannabinoid Receptor 2 Agonist.
-
What are the key routes of administration in the Rectal Cancer pipeline drugs market?
The key routes of administration in the Rectal Cancer pipeline drugs market are Intravenous, Oral, Subcutaneous, Intravenous Drip, Buccal, Intramuscular, Intraperitoneal, Intratumor, Parenteral, Sublingual, Submucosal, Topical, and Vaginal.
-
What are the key molecule types in the Rectal Cancer pipeline drugs market?
The key molecule types in the Rectal Cancer pipeline drugs market are Small Molecule, Monoclonal Antibody, Fusion Protein, Cell Therapy, Recombinant Vector Vaccine, Aptamer, Biologic, Monoclonal Antibody Conjugated, and Oncolytic Virus.
-
What are the major companies in the Rectal Cancer pipeline drugs market?
In the Rectal Cancer pipeline drugs market the major companies are Eisai Co Ltd, GlaxoSmithKline Plc, Jiangsu Hengrui Medicine Co Ltd, Merck KGaA, Novartis AG, SQZ Biotechnologies Co, Advaxis Inc, Alkermes Plc, Amphivena Therapeutics Inc, and Apexigen Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.